Spots Global Cancer Trial Database for immunologic response
Every month we try and update this database with for immunologic response cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
To Detect Cryoimmunologic Response Induced by Early Breast Cancer Ultrasound-guided Cryoablation (ICE-study) | NCT05727813 | Cancer, Treatme... Tumor of Breast Systemic Inflam... Stage I Breast ... | cryoablation | 18 Years - | University of Roma La Sapienza | |
The Correlation Between the Haplotype of Human Leukocyte Antigen (HLA) and Human Papillomavirus | NCT00154479 | Cancer of Cervi... | 18 Years - 80 Years | National Taiwan University Hospital | ||
Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma | NCT00314106 | Metastatic Mela... | Melanoma Reacti... Cyclophosphamid... IL-2 Fludarabine 1200 total body... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma | NCT00273910 | High-Risk Melan... | gp100:209-217 (... Montanide ISA-5... Imiquimod | 7 Years - | National Institutes of Health Clinical Center (CC) | |
Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma | NCT00273910 | High-Risk Melan... | gp100:209-217 (... Montanide ISA-5... Imiquimod | 7 Years - | National Institutes of Health Clinical Center (CC) | |
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma | NCT00059475 | Melanoma | Glycoprotein 10... Interleukin-2 (... Montanide ISA 5... Melanoma antige... 27-35 (27L): me... melanoma antige... | 7 Years - | National Institutes of Health Clinical Center (CC) | |
Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma | NCT00314106 | Metastatic Mela... | Melanoma Reacti... Cyclophosphamid... IL-2 Fludarabine 1200 total body... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma | NCT01363206 | Malignant Melan... | Granulocyte-Mac... Ipilimumab | 18 Years - | Northern California Melanoma Center | |
Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma | NCT01363206 | Malignant Melan... | Granulocyte-Mac... Ipilimumab | 18 Years - | Northern California Melanoma Center |